1-7 of 7
Neil A. O'Brien
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

Neil A. O'Brien, Martina S.J. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M. Madrid, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1365–1375.
https://doi.org/10.1158/1535-7163.MCT-23-0353
Published: 01 December 2023
View article titled, Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers
Open the PDF for Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers in another window
Includes: Supplementary data
Journal Articles

Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies

Neil A. O'Brien, Holly K.T. Huang, Martina S.J. McDermott, Athena M. Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (5): 751–761.
https://doi.org/10.1158/1535-7163.MCT-21-0847
Published: 04 May 2022
View article titled, Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Open the PDF for Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies in another window
Includes: Supplementary data
Journal Articles

EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

Christen Dillard, Meagan Kiyohara, Vei Mah, Sean P. McDermott, Dana Bazzoun, Jessica Tsui, Ann M. Chan, Ghassan Haddad, Matteo Pellegrini, Yu-Ling Chang, Yahya Elshimali, Yanyuan Wu, Jaydutt V. Vadgama, Sara R. Kim, Lee Goodglick, Samuel M. Law, Deven D. Patel, Puneet Dhawan, Neil A. O'Brien, Lynn K. Gordon, Jonathan Braun, Gary Lazar, Max S. Wicha, Madhuri Wadehra
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (8): 1682–1695.
https://doi.org/10.1158/1535-7163.MCT-19-0850
Published: 04 August 2020
View article titled, EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells
Open the PDF for EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells

Gottfried E. Konecny, Teodora Kolarova, Neil A. O'Brien, Boris Winterhoff, Guorong Yang, Jingwei Qi, Zhengdong Qi, Natarajan Venkatesan, Raul Ayala, Tong Luo, Richard S. Finn, Jessica Kristof, Chad Galderisi, Diana Graus Porta, Lee Anderson, Michael M. Shi, Alejandro Yovine, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5): 632–642.
https://doi.org/10.1158/1535-7163.MCT-12-0999
Published: 08 May 2013
View article titled, Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
Open the PDF for Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells in another window
Journal Articles

Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer

Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Amrita J. Desai, Ondrej Kalous, Dylan Conklin, Raul Ayala, Neil A. O'Brien, Cornelia Quadt, Mikhail Akimov, Dennis J. Slamon, Richard S. Finn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (4): 509–519.
https://doi.org/10.1158/1535-7163.MCT-12-0507
Published: 08 April 2013
View article titled, Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
Open the PDF for Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O'Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian Taylor, James G. Christensen, Dennis J. Slamon, Richard S. Finn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (9): 1978–1987.
https://doi.org/10.1158/1535-7163.MCT-11-0730
Published: 06 September 2012
View article titled, Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Open the PDF for Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib in another window
Includes: Supplementary data
Journal Articles

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

Neil A. O'Brien, Brigid C. Browne, Lucy Chow, Yuhua Wang, Charles Ginther, Jane Arboleda, Michael J. Duffy, John Crown, Norma O'Donovan, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1489–1502.
https://doi.org/10.1158/1535-7163.MCT-09-1171
Published: 09 June 2010
View article titled, Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Open the PDF for Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib in another window
Includes: Supplementary data